We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Antidote Developed for Cocaine Overdose

By HospiMedica International staff writers
Posted on 30 Apr 2012
A novel injectable solution could reverse the effects of an otherwise lethal overdose of cocaine in an emergency setting, according to a new study.

Researchers at the Scripps Research Institute (La Jolla, CA, USA) developed the antidote, a ready-made solution of antibodies that works as a passive vaccine, much like those used to treat snakebite, using a genetically engineered mouse to produce antibodies against cocaine. More...
The best of these antibodies, called GNCgzk, showed ten times the cocaine-binding affinity of GNC92H2, a molecule developed by the same team in 2005 in a murine model. The drug-specific antibodies swiftly remove cocaine from the bloodstream, reducing direct effects on the heart and nearby organs. In addition, since the cocaine molecules are also small enough to cross the blood-brain barrier (BBB), the sudden lowering of bloodstream concentration causes them to diffuse rapidly out of brain tissue, protecting the brain.

4In a preliminary test, the scientists showed that an injection of GNCgzk antibodies 30 minutes before an injection of a lethal cocaine dose greatly reduced the signs of overdose--such as awkward movements and seizures--and kept all treated mice alive. By contrast, about half of untreated mice and 15% of GNC92H2-treated mice died. In another test that better simulated a real-life emergency situation, mice were first given a cocaine overdose, and three minutes later were infused with GNCgzk. About half of untreated mice were killed by such a dose, GNC92H2 reduced that rate to about 28%, and the new GNCgzk antibodies reduced the mortality rate further, to 20%.

More strikingly, a stripped-down version of GNCgzk dubbed F(ab')2-gzk, which contains only the antibody's cocaine-binding segments, reduced the mortality to zero, as well as significantly reducing overdose signs such as seizures. The researchers are now trying to find ways to produce the F(ab')2-gzk antidote economically and in large quantities. Such a treatment could be useful not only in reducing the immediate effects of an overdose, but also in preventing near-term relapses. It could be administered to patients in addiction recovery or detoxification programs as a prophylactic treatment to supplement other medications, such as antidepressants, and counseling. The study was published in the April 2012 issue of Molecular Pharmaceutics.

“This would be the first specific antidote for cocaine toxicity,” said senior author Kim Janda, PhD, a professor in the department of immunology and microbial science. “It's a human antibody so it should be relatively safe, it has a superior affinity for cocaine, and we examined it in a cocaine overdose model that mirrors a real-life scenario.”

Related Links:
Scripps Research Institute



New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Gold Member
12-Channel ECG
CM1200B
New
Blood Gas Analyzer
i-Check200
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Six-month FlexPulse IDE data show positive outcomes with Abbott’s TactiFlex Duo catheter, confirming safety and efficacy seen in the CE Mark study for complex AFib (photo courtesy of Abbott)

Dual-Energy Ablation and Conduction System Pacing Show Positive Early Outcomes

Atrial fibrillation and other arrhythmias are common in both hospitalized and ambulatory patients, often complicating hemodynamic stability, stroke prevention, and perioperative care. Within this context,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.